JP2007515469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007515469A5 JP2007515469A5 JP2006546357A JP2006546357A JP2007515469A5 JP 2007515469 A5 JP2007515469 A5 JP 2007515469A5 JP 2006546357 A JP2006546357 A JP 2006546357A JP 2006546357 A JP2006546357 A JP 2006546357A JP 2007515469 A5 JP2007515469 A5 JP 2007515469A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- use according
- patient
- group
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (10)
- 患者のガンを治療するための医薬の製造におけるCD40アゴニスト抗体またはそのフラグメントの使用であって、該医薬は、CD40アゴニスト抗体またはそのフラグメントを患者に送達するために1mg/kg未満の用量で投与され、そして投与されるその医薬により該抗体のCmax血清濃度が50μg/ml未満になることを特徴とする、上記使用。
- 抗体は、抗体3.1.1、3.1.1H−A78T、3.1.1H−A78T−V88A−V97A、3.1.1H−A78T−V88A−V97A/3.1.1L−L4M−L83V、7.1.2、10.8.3、15.1.1、21.4.1、21.2.1、22.1.1、22.1.1H−C109A、23.5.1、23.25.1、23.28.1、23.28.1H−D16E、23.29.1、24.2.1、3.1.1L−L4M−L83V、および、23.28.1L−C92Aのアミノ酸配列を有する抗体からなる群より選択される、請求項1に記載の使用。
- 抗体は、3.1.1、3.1.1H−A78T、3.1.1H−A78T−V88A−V97A、3.1.1H−A78T−V88A−V97A/3.1.1L−L4M−L83V、7.1.2、10.8.3、15.1.1、21.4.1、21.2.1、22.1.1、22.1.1H−C109A、23.5.1、23.25.1、23.28.1、23.28.1H−D16E、23.29.1、24.2.1、3.1.1L−L4M−L83V、および、23.28.1L−C92Aと称される抗体からなる群より選択される抗体のCDRまたは可変領域を含む、請求項1に記載の使用。
- 抗体は、21.4.1、3.1.1、および、3.1.1H−A78T−V88A−V97A/3.1.1L−L4M−L83Vからなる群より選択される抗体のアミノ酸配列を有する、請求項2に記載の使用。
- 患者の腫瘍を治療するための医薬の製造におけるCD40アゴニスト抗体またはそのフラグメントの使用であって、該医薬は、治療上有効な量のDNA複製阻害剤との組み合わせで患者に投与されることを特徴とする、上記使用。
- CD40アゴニスト抗体および製薬上許容できるキャリアーを含む非経口投与に適した安定な液体医薬製剤であって、該製剤は少なくとも3ヶ月の期間安定であり、該CD40アゴニスト抗体の濃度は少なくとも5mg/mlであり、そして製薬上許容できるキャリアーは酢酸ナトリウム、塩化ナトリウムおよびポリソルベート80を含むことを特徴とする、上記製剤。
- 抗CD40抗体は、21.4.1、3.1.1、および、3.1.1H−A78T−V88A−V97A/3.1.1L−L4M−L83Vからなる群より選択される抗体のアミノ酸配列を有する、請求項6に記載の製剤。
- 用量は、0.1〜0.3mg/kgであり、患者における抗体のCmax血清濃度は、0.5〜10μg/mlである、請求項1に記載の使用。
- DNA複製阻害剤がシスプラチンである、請求項5に記載の使用。
- 抗体が、21.4.1、3.1.1、および3.1.1H−A78T−V88A−V97A/3.1.1L−L4M−L83Vからなる群より選択される抗体のアミノ酸配列を有する、請求項9に記載の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53163903P | 2003-12-22 | 2003-12-22 | |
PCT/IB2004/004103 WO2005063289A1 (en) | 2003-12-22 | 2004-12-09 | Cd40 antibody formulation and methods |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011100868A Division JP5634321B2 (ja) | 2003-12-22 | 2011-04-28 | Cd40抗体製剤および方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007515469A JP2007515469A (ja) | 2007-06-14 |
JP2007515469A5 true JP2007515469A5 (ja) | 2008-01-31 |
Family
ID=34738672
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006546357A Pending JP2007515469A (ja) | 2003-12-22 | 2004-12-09 | Cd40抗体製剤および方法 |
JP2011100868A Expired - Fee Related JP5634321B2 (ja) | 2003-12-22 | 2011-04-28 | Cd40抗体製剤および方法 |
JP2014121342A Pending JP2014205692A (ja) | 2003-12-22 | 2014-06-12 | Cd40抗体製剤および方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011100868A Expired - Fee Related JP5634321B2 (ja) | 2003-12-22 | 2011-04-28 | Cd40抗体製剤および方法 |
JP2014121342A Pending JP2014205692A (ja) | 2003-12-22 | 2014-06-12 | Cd40抗体製剤および方法 |
Country Status (20)
Country | Link |
---|---|
US (4) | US20050136055A1 (ja) |
EP (3) | EP2218461B1 (ja) |
JP (3) | JP2007515469A (ja) |
KR (2) | KR20080023766A (ja) |
CN (2) | CN102552905A (ja) |
AU (1) | AU2004308749B2 (ja) |
BR (1) | BRPI0418029B8 (ja) |
CA (2) | CA2549652C (ja) |
DK (1) | DK2218461T3 (ja) |
ES (1) | ES2580002T3 (ja) |
HU (1) | HUE027717T2 (ja) |
IL (2) | IL175540A (ja) |
NO (1) | NO343797B1 (ja) |
NZ (2) | NZ583179A (ja) |
PL (1) | PL2218461T3 (ja) |
RU (1) | RU2355421C2 (ja) |
SI (1) | SI2218461T1 (ja) |
TW (1) | TWI359671B (ja) |
WO (1) | WO2005063289A1 (ja) |
ZA (1) | ZA200603804B (ja) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
BRPI0619586A2 (pt) * | 2005-12-09 | 2018-08-28 | Seattle Genetics Inc | método para o tratamento ou prevenção de um distúrbio associado com cd40 |
MX2008013993A (es) | 2006-05-03 | 2009-05-11 | Univ Colorado | Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular. |
US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
AU2008260498B2 (en) | 2007-05-30 | 2012-11-29 | Xencor, Inc. | Methods and compositions for inhibiting CD32b expressing cells |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
CA2735421A1 (en) * | 2008-08-29 | 2010-03-04 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Delivery of a cd40 agonist to a tumor draining lymph node of a subject |
US9561214B2 (en) * | 2008-10-16 | 2017-02-07 | Array Biopharma Inc. | Method of treatment using inhibitors of mitosis |
WO2011101332A1 (en) | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
WO2012123269A1 (en) | 2011-03-11 | 2012-09-20 | Proyecto De Biomedicina Cima, S.L. | Immunogenic compositions and methods for their use |
EP2505640A1 (en) | 2011-03-29 | 2012-10-03 | Neo Virnatech, S.L. | Vaccine compositions for birnavirus-borne diseases |
MX339239B (es) | 2011-04-29 | 2016-05-18 | Apexigen Inc | Anticuerpos anti-cd40 y metodos de uso. |
PE20142406A1 (es) | 2012-05-04 | 2015-01-23 | Pfizer | Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna |
FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
CN104918957B (zh) | 2012-10-30 | 2018-11-16 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
US9856319B2 (en) | 2012-12-28 | 2018-01-02 | Abbvie Inc. | Monovalent binding proteins |
US10533054B2 (en) | 2013-01-31 | 2020-01-14 | Thomas Jefferson University | Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system |
US11273204B2 (en) | 2013-08-08 | 2022-03-15 | Cytune Pharma | IL-15 and IL-15RAPLHA sushi domain based immunocytokines |
JP6691113B2 (ja) | 2014-10-29 | 2020-04-28 | シアトル ジェネティックス, インコーポレイテッド | 非フコシル化抗cd40抗体の投与量および投与 |
JP2018521983A (ja) | 2015-07-16 | 2018-08-09 | バイオカイン セラピューティックス リミテッド | がんを治療するための組成物および方法 |
EP3426271A4 (en) | 2016-03-10 | 2019-10-16 | Cold Genesys, Inc. | METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY POLYTHERAPY |
EP3468997B1 (en) | 2016-06-08 | 2023-09-13 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗pd-l1およびil-2サイトカイン |
US11905331B2 (en) | 2016-11-11 | 2024-02-20 | Kumho Ht, Inc. | Antibody binding specifically to CD40 and use thereof |
WO2018162450A1 (en) | 2017-03-06 | 2018-09-13 | Fundación Para La Investigación Médica Aplicada | New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells |
KR102198998B1 (ko) * | 2017-06-01 | 2021-01-07 | 서울대학교 산학협력단 | 신규한 항-cd40 항체 및 이의 용도 |
TW201902462A (zh) * | 2017-06-02 | 2019-01-16 | 瑞士商赫孚孟拉羅股份公司 | 用於免疫促效劑之新穎投與途徑 |
EP3418302A1 (en) * | 2017-06-19 | 2018-12-26 | F. Hoffmann-La Roche AG | Administration routes for immune agonists |
WO2019204756A1 (en) * | 2018-04-20 | 2019-10-24 | Lyvgen Biopharma Co., Ltd. | Anti-cd40 antibodies and uses thereof |
CA3103629A1 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
KR20210070317A (ko) | 2018-09-28 | 2021-06-14 | 리브젠 바이오파마 코., 엘티디. | 조작된 Fc 도메인을 갖는 항-CD40 결합 분자 및 그의 치료적 용도 |
EP3939998A4 (en) | 2018-11-30 | 2022-08-10 | Jiangsu Hengrui Medicine Co., Ltd. | PHARMACEUTICAL COMPOSITION WITH CD40 ANTIBODY AND USE THEREOF |
EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
AU2021300362A1 (en) | 2020-07-01 | 2023-02-23 | ARS Pharmaceuticals, Inc. | Anti-ASGR1 antibody conjugates and uses thereof |
CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
KR20240026507A (ko) | 2021-06-29 | 2024-02-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도 |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5247069A (en) * | 1986-06-13 | 1993-09-21 | Oncogen | Ligands and methods for augmenting B-cell proliferation |
JP2547556B2 (ja) * | 1987-02-06 | 1996-10-23 | 株式会社 ミドリ十字 | r−グロブリンの液状製剤 |
SE8701004D0 (sv) | 1987-03-11 | 1987-03-11 | Astra Ab | Method for therapy of leukemias and certain other malignancies |
JPH03204821A (ja) * | 1989-12-28 | 1991-09-06 | Green Cross Corp:The | モノクローナル抗体含有水溶液の加熱処理方法 |
CA2089229C (en) * | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
AU5098493A (en) | 1992-08-21 | 1994-03-15 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
ES2211884T3 (es) * | 1993-10-01 | 2004-07-16 | Immunex Corporation | Anticuerpos contra el cd40. |
ATE267607T1 (de) * | 1993-12-23 | 2004-06-15 | Immunex Corp | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten |
GB9425060D0 (en) | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
DE69810481T2 (de) * | 1997-06-13 | 2003-09-25 | Genentech Inc | Stabilisierte antikörperformulierung |
ES2557768T3 (es) * | 1999-06-01 | 2016-01-28 | Biogen Ma Inc. | Un anticuerpo monoclonal bloqueante frente a VLA-1 y su uso para el tratamiento de trastornos inflamatorios |
US6358670B1 (en) * | 1999-12-28 | 2002-03-19 | Electron Vision Corporation | Enhancement of photoresist plasma etch resistance via electron beam surface cure |
US20030124119A1 (en) * | 1999-12-28 | 2003-07-03 | Tadao Yamazaki | Stable antibody compositions and injection preparations |
EP1975182A1 (en) | 2000-02-01 | 2008-10-01 | PanGenetics B.V. | CD40-binding APC-activating molecules |
US6838250B2 (en) | 2000-03-31 | 2005-01-04 | Ortho-Clinical Diagnostics, Inc. | Immunoassay for C-reactive protein |
KR20020091170A (ko) * | 2000-03-31 | 2002-12-05 | 아이덱 파마슈티칼즈 코포레이션 | B 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-cd20의 조합된 사용 |
US7063845B2 (en) * | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
US7015194B2 (en) * | 2000-05-10 | 2006-03-21 | Novo Nordisk A/S | Pharmaceutical composition comprising factor VIIa and anti-TFPI |
DE60143535D1 (de) * | 2000-10-02 | 2011-01-05 | Novartis Vaccines & Diagnostic | Humane antikörper gegen cd40 |
IL155002A0 (en) * | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
JP4317010B2 (ja) * | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | IgG抗体の安定な凍結乾燥医薬製剤 |
KR100913714B1 (ko) * | 2001-11-08 | 2009-08-24 | 패시트 바이오테크 코포레이션 | Igg 항체의 안정한 액상 약학 제형물 |
AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
ATE395413T1 (de) * | 2001-12-03 | 2008-05-15 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
US7115108B2 (en) | 2002-04-02 | 2006-10-03 | Becton, Dickinson And Company | Method and device for intradermally delivering a substance |
US20080009439A1 (en) * | 2002-11-05 | 2008-01-10 | Alsobrook John P | Compositions and Methods of Use for a Fibroblast Growth Factor |
HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
-
2004
- 2004-12-02 US US11/001,980 patent/US20050136055A1/en not_active Abandoned
- 2004-12-09 CN CN2012100028652A patent/CN102552905A/zh active Pending
- 2004-12-09 CA CA2549652A patent/CA2549652C/en active Active
- 2004-12-09 AU AU2004308749A patent/AU2004308749B2/en not_active Ceased
- 2004-12-09 HU HUE10162787A patent/HUE027717T2/en unknown
- 2004-12-09 BR BRPI0418029A patent/BRPI0418029B8/pt not_active IP Right Cessation
- 2004-12-09 SI SI200432321A patent/SI2218461T1/sl unknown
- 2004-12-09 JP JP2006546357A patent/JP2007515469A/ja active Pending
- 2004-12-09 EP EP10162787.5A patent/EP2218461B1/en active Active
- 2004-12-09 WO PCT/IB2004/004103 patent/WO2005063289A1/en active Application Filing
- 2004-12-09 PL PL10162787.5T patent/PL2218461T3/pl unknown
- 2004-12-09 KR KR1020087004912A patent/KR20080023766A/ko not_active Application Discontinuation
- 2004-12-09 CA CA2704300A patent/CA2704300A1/en not_active Abandoned
- 2004-12-09 EP EP16164228.5A patent/EP3081933A1/en not_active Withdrawn
- 2004-12-09 CN CNA2004800385418A patent/CN1897971A/zh active Pending
- 2004-12-09 EP EP04801378A patent/EP1706143A1/en not_active Ceased
- 2004-12-09 KR KR1020067012364A patent/KR100847944B1/ko active IP Right Grant
- 2004-12-09 RU RU2006120950/14A patent/RU2355421C2/ru active
- 2004-12-09 DK DK10162787.5T patent/DK2218461T3/en active
- 2004-12-09 NZ NZ583179A patent/NZ583179A/en not_active IP Right Cessation
- 2004-12-09 NZ NZ547162A patent/NZ547162A/en not_active IP Right Cessation
- 2004-12-09 ES ES10162787.5T patent/ES2580002T3/es active Active
- 2004-12-21 TW TW093139794A patent/TWI359671B/zh not_active IP Right Cessation
-
2006
- 2006-05-10 IL IL175540A patent/IL175540A/en active IP Right Grant
- 2006-05-12 ZA ZA200603804A patent/ZA200603804B/en unknown
- 2006-07-20 NO NO20063373A patent/NO343797B1/no not_active IP Right Cessation
-
2009
- 2009-07-14 US US12/502,587 patent/US20090311254A1/en not_active Abandoned
- 2009-10-11 IL IL201409A patent/IL201409A0/en unknown
-
2010
- 2010-12-23 US US12/978,272 patent/US20110104182A1/en not_active Abandoned
-
2011
- 2011-04-28 JP JP2011100868A patent/JP5634321B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-19 US US13/424,260 patent/US20120263732A1/en not_active Abandoned
-
2014
- 2014-06-12 JP JP2014121342A patent/JP2014205692A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007515469A5 (ja) | ||
CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
JP2012067116A5 (ja) | ||
CN109562281B (zh) | 酚类trpv1激动剂的前药与局部麻醉药和血管收缩剂联合用于改善局部麻醉 | |
RU2007132181A (ru) | ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ | |
JP2005515966A5 (ja) | ||
JP2008507536A5 (ja) | ||
JP2014114288A5 (ja) | ||
EP2387401A1 (en) | Method for treating colorectal cancer | |
JP2006513184A5 (ja) | ||
TWI441639B (zh) | 用於治療卵巢癌之包含紫杉醇之組合 | |
JP2002544231A5 (ja) | ||
JP2004525143A5 (ja) | ||
JP2006514681A5 (ja) | ||
JP2024016209A5 (ja) | ||
JP2015508781A (ja) | 癌の治療 | |
TWI341728B (en) | Combinations comprising epothilones and anti-metabolites | |
WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
JP2007504268A5 (ja) | ||
JP2006508118A5 (ja) | ||
WO2021129616A1 (zh) | 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法 | |
CN111065412B (zh) | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 | |
JP2005508323A5 (ja) | ||
KR20120104574A (ko) | 티보자닙과 템시롤리무스의 조합물 |